Zhihuang Hu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Zhihuang Hu has a total of 201 co-authors. Here are the top co-authors by number of shared publications:
- Li Zhang
Sun Yat-sen University Cancer Center
6 shared publications Yan Huang
State Key Laboratory of Oncology in South China, Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China
6 shared publicationsYuanyuan Zhao
5 shared publicationsHongyun Zhao
4 shared publications- Jialei Wang
Department of Thoracic Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
4 shared publications Cong Xue
3 shared publications
Latest Publications
- Open Access
- 14 October 2026
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (10) , e015873
Plasma cell-free RNA ITGB3 is associated with long-term clinical benefit in patients with non-small cell lung cancer receiving immunochemotherapy
Predicting sustained clinical benefit from immunochemotherapy in advanced non-small cell lung cancer (NSCLC) remains a major challenge. This study aimed to identify plasma cell-free RNA (cfRNA) biomarkers for predicting long-term progression-free survival (PFS ≥24 months). Extracellular vesicle-enriched cfRNA sequencing was performed on 165 patients with advanced NSCLC (discovery cohort, n=82; prospective validation cohort, n=83) and 50 healthy controls. A multistep screening approach, including differential expression and Cox regression analyses, was used to identify candidate biomarkers, which were further validated by reverse-transcription quantitative PCR. ITGB3 was identified as the most robust prognostic biomarker. Low baseline ITGB3 expression was significantly associated with superior survival outcomes. In the discovery cohort, the median PFS was 25.8 months for the ITGB3-low group versus 8.4 months for the ITGB3-high group (HR 0.325, pITGB3 demonstrated high prognostic accuracy with areas under the curve (AUCs) of 0.760 and 0.796 in the discovery and validation cohorts, respectively. Combining ITGB3 with three-level programmed death-ligand 1 (PD-L1) status yielded an AUC of 0.812, suggesting that the two biomarkers may provide complementary prognostic information. Multivariable analysis confirmed baseline ITGB3 as an independent prognostic factor for both PFS (HR=1.27, pITGB3 is a robust, non-invasive biomarker for identifying patients likely to achieve long-term benefit from immunochemotherapy, providing complementary value to traditional PD-L1 assessment.
- 14 October 2026
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (10) , e015873
Open AccessPlasma cell-free RNA ITGB3 is associated with long-term clinical benefit in patients with non-small cell lung cancer receiving immunochemotherapy
Predicting sustained clinical benefit from immunochemotherapy in advanced non-small cell lung cancer (NSCLC) remains a major challenge. This study aimed to identify plasma cell-free RNA (cfRNA) biomarkers for predicting long-term progression-free survival (PFS ≥24 months). Extracellular vesicle-enriched cfRNA sequencing was performed on 165 patients with advanced NSCLC (discovery cohort, n=82; prospective validation cohort, n=83) and 50 healthy controls. A multistep screening approach, including differential expression and Cox regression analyses, was used to identify candidate biomarkers, which were further validated by reverse-transcription quantitative PCR. ITGB3 was identified as the most robust prognostic biomarker. Low baseline ITGB3 expression was significantly associated with superior survival outcomes. In the discovery cohort, the median PFS was 25.8 months for the ITGB3-low group versus 8.4 months for the ITGB3-high group (HR 0.325, pITGB3 demonstrated high prognostic accuracy with areas under the curve (AUCs) of 0.760 and 0.796 in the discovery and validation cohorts, respectively. Combining ITGB3 with three-level programmed death-ligand 1 (PD-L1) status yielded an AUC of 0.812, suggesting that the two biomarkers may provide complementary prognostic information. Multivariable analysis confirmed baseline ITGB3 as an independent prognostic factor for both PFS (HR=1.27, pITGB3 is a robust, non-invasive biomarker for identifying patients likely to achieve long-term benefit from immunochemotherapy, providing complementary value to traditional PD-L1 assessment.
- Open Access
- 28 September 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1915711
Clinical outcomes and prognostic factors of Ommaya reservoir-based intrathecal chemotherapy in lung cancer leptomeningeal metastasis: a retrospective cohort study
Objectives: To evaluate clinical outcomes and identify prognostic determinants in patients with lung cancer leptomeningeal metastasis (LCLM) treated with Ommaya reservoir-based intrathecal (IT) chemotherapy. Method: We retrospectively reviewed 154 LCLM patients treated at Fudan University Shanghai Cancer Center (2022-2025). All patients underwent Ommaya reservoir implantation, or combined with VP shunt. IT pemetrexed (30 mg/week) was delivered for 4–6 consecutive weeks. Clinical characteristics, cerebrospinal fluid (CSF) and magnetic resonance imaging (MRI) features were collected. Survival outcomes were assessed using Kaplan–Meier and Cox regression analyses. Results: The cohort had a median age of 59 years (IQR, 53-65) with predominance of female sex (59.1%), lung adenocarcinoma (98.1%), and EGFR mutations (76.7%). Median overall survival (OS) for the entire cohort was 331 days (IQR, 266–446). To provide guidance on clinical decision making, we established an exploratory four-tier prognostic system integrating KPS and intracranial pressure (ICP), categorizing patients into distinct prognostic quartiles. Our analysis revealed that among patients with Karnofsky Performance Status (KPS) ≥70, a normal ICP was associated with superior survival. Conversely, in patients with KPS ≤ 50, a decrease in intracranial pressure indicates a poorer prognosis for the patients. Multivariate Cox regression identified KPS, extracranial metastasis, MRI morphology, and CSF glucose/protein as independent prognostic factors. A nomogram developed from these variables showed excellent discrimination (AUC = 0.894) and robust calibration. Conclusions: This study establishes a practical risk stratification system and a prognostic nomogram to assist individualized clinical decision-making for LCLM patients.
- 28 September 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1915711
Open AccessClinical outcomes and prognostic factors of Ommaya reservoir-based intrathecal chemotherapy in lung cancer leptomeningeal metastasis: a retrospective cohort study
Objectives: To evaluate clinical outcomes and identify prognostic determinants in patients with lung cancer leptomeningeal metastasis (LCLM) treated with Ommaya reservoir-based intrathecal (IT) chemotherapy. Method: We retrospectively reviewed 154 LCLM patients treated at Fudan University Shanghai Cancer Center (2022-2025). All patients underwent Ommaya reservoir implantation, or combined with VP shunt. IT pemetrexed (30 mg/week) was delivered for 4–6 consecutive weeks. Clinical characteristics, cerebrospinal fluid (CSF) and magnetic resonance imaging (MRI) features were collected. Survival outcomes were assessed using Kaplan–Meier and Cox regression analyses. Results: The cohort had a median age of 59 years (IQR, 53-65) with predominance of female sex (59.1%), lung adenocarcinoma (98.1%), and EGFR mutations (76.7%). Median overall survival (OS) for the entire cohort was 331 days (IQR, 266–446). To provide guidance on clinical decision making, we established an exploratory four-tier prognostic system integrating KPS and intracranial pressure (ICP), categorizing patients into distinct prognostic quartiles. Our analysis revealed that among patients with Karnofsky Performance Status (KPS) ≥70, a normal ICP was associated with superior survival. Conversely, in patients with KPS ≤ 50, a decrease in intracranial pressure indicates a poorer prognosis for the patients. Multivariate Cox regression identified KPS, extracranial metastasis, MRI morphology, and CSF glucose/protein as independent prognostic factors. A nomogram developed from these variables showed excellent discrimination (AUC = 0.894) and robust calibration. Conclusions: This study establishes a practical risk stratification system and a prognostic nomogram to assist individualized clinical decision-making for LCLM patients.
- 11 September 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (37)
Mutant p53 sensitizes KRAS-driven lung adenocarcinoma to immunotherapy by repressing SPP1
The efficacy of immune checkpoint blockade (ICB) in lung adenocarcinoma (LUAD) is limited by primary or acquired resistance, especially in genetically defined subsets. We investigated the impact of KRAS/TP53 co-mutation on ICB response. Our analysis reveals that KRAS/TP53 co-mutation is associated with favorable ICB outcomes, a phenotype orchestrated by secreted phosphoprotein 1 (SPP1). Mechanistically, mutant p53 and KRAS exert opposing effects on SPP1. Mutant p53 synergizes with transcription factor FOXA1 to repress SPP1 transcription, whereas KRAS activates the mitogen-activated protein kinase (MAPK)–extracellular signal–regulated kinase (ERK)–signal transducer and activator of transcription 1 (STAT1) axis to up-regulate SPP1 . Consequently, reduced SPP1 level in KRAS/TP53 co-mutant LUAD impairs myeloid-derived suppressor cell (MDSC) recruitment and increases CD8+ T cell infiltration. Notably, SPP1 blockade synergizes with anti–programmed death-1 (PD-1) therapy to suppress tumor growth in KRAS -mutant xenograft models. Collectively, we delineate a mutant p53–FOXA1–SPP1 regulatory axis that modulates ICB susceptibility and unveil a synergistic combination therapy strategy.
- 11 September 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (37)
Mutant p53 sensitizes KRAS-driven lung adenocarcinoma to immunotherapy by repressing SPP1
The efficacy of immune checkpoint blockade (ICB) in lung adenocarcinoma (LUAD) is limited by primary or acquired resistance, especially in genetically defined subsets. We investigated the impact of KRAS/TP53 co-mutation on ICB response. Our analysis reveals that KRAS/TP53 co-mutation is associated with favorable ICB outcomes, a phenotype orchestrated by secreted phosphoprotein 1 (SPP1). Mechanistically, mutant p53 and KRAS exert opposing effects on SPP1. Mutant p53 synergizes with transcription factor FOXA1 to repress SPP1 transcription, whereas KRAS activates the mitogen-activated protein kinase (MAPK)–extracellular signal–regulated kinase (ERK)–signal transducer and activator of transcription 1 (STAT1) axis to up-regulate SPP1 . Consequently, reduced SPP1 level in KRAS/TP53 co-mutant LUAD impairs myeloid-derived suppressor cell (MDSC) recruitment and increases CD8+ T cell infiltration. Notably, SPP1 blockade synergizes with anti–programmed death-1 (PD-1) therapy to suppress tumor growth in KRAS -mutant xenograft models. Collectively, we delineate a mutant p53–FOXA1–SPP1 regulatory axis that modulates ICB susceptibility and unveil a synergistic combination therapy strategy.
- Open Access
- 11 September 2026
- Published by Wiley in Clinical and Translational Medicine
- Vol. 16 (9) , e70814
Bevacizumab plus nab‐paclitaxel and platinum as second‐line therapy for driver‐gene‐negative non‐squamous non‐small cell lung cancer after immunochemotherapy: A prospective single‐arm single‐centre study
Background: Effective second‐line therapy is urgently needed for patients with driver‐gene‐negative non‐squamous non‐small cell lung cancer (nsqNSCLC) who progress after first‐line immunochemotherapy. This study aims to evaluate the efficacy and safety of bevacizumab combined with nab‐paclitaxel and platinum (the BAP regimen) in this setting. Methods: This prospective, single‐arm, single‐centre study enrolled 56 patients with advanced driver‐gene‐negative nsqNSCLC failing first‐line immunochemotherapy. Patients received bevacizumab, nab‐paclitaxel, and platinum (carboplatin or cisplatin) for 4–6 cycles, followed by bevacizumab maintenance. The primary endpoint was objective response rate (ORR). Secondary endpoints included progression‐free survival (PFS), overall survival (OS), disease control rate (DCR) and safety. Results: All patients had failed first‐line platinum‐based immunochemotherapy. The confirmed ORR was 46.4% (26/56, 95% confidence interval [CI]: 34.0%–59.3%, p < 0.001), and DCR was 75%. The median PFS and OS were 5.6 (95% CI: 4.35–6.79) and 18.8 (95% CI: 10.31–27.24) months. Patients with ≤ 2 metastatic organs had a significantly longer median PFS than those with >2 metastatic organs ( p = 0.014). Multivariable Cox analysis showed that a platinum‐free interval <6 months was an independent biomarker of worse PFS. The safety profile was manageable. Plasma proteomics identified baseline high TWEAK level as a potential biomarker for response to both the second‐line BAP regimen and first‐line immunochemotherapy. Patients with high baseline TWEAK levels before first‐line immunochemotherapy showed a median OS of 39.8 months under this sequential treatment modality. Conclusions: The BAP regimen demonstrated preliminary efficacy with manageable safety as a second‐line therapy for patients with advanced driver‐gene‐negative nsqNSCLC after immunochemotherapy. Plasma TWEAK levels may serve as a potential biomarker to help identify patients who might benefit most from this sequential treatment modality, pending further independent validation. Further studies are needed.
- 11 September 2026
- Published by Wiley in Clinical and Translational Medicine
- Vol. 16 (9) , e70814
Open AccessBevacizumab plus nab‐paclitaxel and platinum as second‐line therapy for driver‐gene‐negative non‐squamous non‐small cell lung cancer after immunochemotherapy: A prospective single‐arm single‐centre study
Background: Effective second‐line therapy is urgently needed for patients with driver‐gene‐negative non‐squamous non‐small cell lung cancer (nsqNSCLC) who progress after first‐line immunochemotherapy. This study aims to evaluate the efficacy and safety of bevacizumab combined with nab‐paclitaxel and platinum (the BAP regimen) in this setting. Methods: This prospective, single‐arm, single‐centre study enrolled 56 patients with advanced driver‐gene‐negative nsqNSCLC failing first‐line immunochemotherapy. Patients received bevacizumab, nab‐paclitaxel, and platinum (carboplatin or cisplatin) for 4–6 cycles, followed by bevacizumab maintenance. The primary endpoint was objective response rate (ORR). Secondary endpoints included progression‐free survival (PFS), overall survival (OS), disease control rate (DCR) and safety. Results: All patients had failed first‐line platinum‐based immunochemotherapy. The confirmed ORR was 46.4% (26/56, 95% confidence interval [CI]: 34.0%–59.3%, p < 0.001), and DCR was 75%. The median PFS and OS were 5.6 (95% CI: 4.35–6.79) and 18.8 (95% CI: 10.31–27.24) months. Patients with ≤ 2 metastatic organs had a significantly longer median PFS than those with >2 metastatic organs ( p = 0.014). Multivariable Cox analysis showed that a platinum‐free interval <6 months was an independent biomarker of worse PFS. The safety profile was manageable. Plasma proteomics identified baseline high TWEAK level as a potential biomarker for response to both the second‐line BAP regimen and first‐line immunochemotherapy. Patients with high baseline TWEAK levels before first‐line immunochemotherapy showed a median OS of 39.8 months under this sequential treatment modality. Conclusions: The BAP regimen demonstrated preliminary efficacy with manageable safety as a second‐line therapy for patients with advanced driver‐gene‐negative nsqNSCLC after immunochemotherapy. Plasma TWEAK levels may serve as a potential biomarker to help identify patients who might benefit most from this sequential treatment modality, pending further independent validation. Further studies are needed.
- Open Access
Artificial Intelligence-Assisted Prediction of Immunotherapy Benefit and Recurrence Risk Stratification in Gastric Cancer: A Single-Center Real-World Study
Immune checkpoint inhibitors targeting the PD-1 pathway have improved outcomes in advanced gastric cancer; however, substantial heterogeneity in treatment response remains. Current prediction strategies mainly rely on pretreatment biomarkers, which provide static assessments and may not capture the evolving interactions between tumor progression and host immunity. This study aimed to develop a dynamic prediction framework integrating longitudinal clinical trajectories and immune remodeling for continuous risk assessment during PD-1 inhibitor therapy. Methods: This retrospective study included 171 patients with gastric cancer receiving PD-1 inhibitor-based treatment. A landmark analysis framework was established using sequential 28-day follow-up windows to predict subsequent progressive disease (PD) or recurrence based on available clinical and immune information. Three nested models were developed: a baseline model (M0), a dynamic clinical model (M1), and an immune-integrated model (M2) incorporating longitudinal lymphocyte subset features. Model performance was evaluated using discrimination, calibration, and internal validation with patient-level resampling strategies. Results: Predictive performance improved progressively with incorporation of longitudinal information. The ROC AUC increased from 0.559 (95% CI, 0.429–0.690) in M0 to 0.737 (95% CI, 0.613–0.852) in M1 and 0.786 (95% CI, 0.681–0.883) in M2. Dynamic clinical information significantly improved discrimination compared with baseline prediction (ΔAUC = 0.178, p = 0.025), while additional immune features further enhanced risk stratification (ΔAUC = 0.049, p = 0.040). Interpretation analysis identified tumor burden evolution, neutrophil-to-lymphocyte ratio trajectories, and immune functional axes involving T-cell, innate cytotoxicity, and humoral immunity as major contributors to risk estimation. Landmark analyses demonstrated the feasibility of continuously updating PD/recurrence risk during treatment. Conclusions: This study establishes a dynamic landmark prediction framework integrating longitudinal clinical trajectories and immune remodeling for continuous risk assessment during PD-1 inhibitor therapy. Dynamic clinical and immune features provided complementary predictive information beyond baseline characteristics, supporting an adaptive approach for precision immunotherapy monitoring in gastric cancer.
Open AccessArtificial Intelligence-Assisted Prediction of Immunotherapy Benefit and Recurrence Risk Stratification in Gastric Cancer: A Single-Center Real-World Study
Immune checkpoint inhibitors targeting the PD-1 pathway have improved outcomes in advanced gastric cancer; however, substantial heterogeneity in treatment response remains. Current prediction strategies mainly rely on pretreatment biomarkers, which provide static assessments and may not capture the evolving interactions between tumor progression and host immunity. This study aimed to develop a dynamic prediction framework integrating longitudinal clinical trajectories and immune remodeling for continuous risk assessment during PD-1 inhibitor therapy. Methods: This retrospective study included 171 patients with gastric cancer receiving PD-1 inhibitor-based treatment. A landmark analysis framework was established using sequential 28-day follow-up windows to predict subsequent progressive disease (PD) or recurrence based on available clinical and immune information. Three nested models were developed: a baseline model (M0), a dynamic clinical model (M1), and an immune-integrated model (M2) incorporating longitudinal lymphocyte subset features. Model performance was evaluated using discrimination, calibration, and internal validation with patient-level resampling strategies. Results: Predictive performance improved progressively with incorporation of longitudinal information. The ROC AUC increased from 0.559 (95% CI, 0.429–0.690) in M0 to 0.737 (95% CI, 0.613–0.852) in M1 and 0.786 (95% CI, 0.681–0.883) in M2. Dynamic clinical information significantly improved discrimination compared with baseline prediction (ΔAUC = 0.178, p = 0.025), while additional immune features further enhanced risk stratification (ΔAUC = 0.049, p = 0.040). Interpretation analysis identified tumor burden evolution, neutrophil-to-lymphocyte ratio trajectories, and immune functional axes involving T-cell, innate cytotoxicity, and humoral immunity as major contributors to risk estimation. Landmark analyses demonstrated the feasibility of continuously updating PD/recurrence risk during treatment. Conclusions: This study establishes a dynamic landmark prediction framework integrating longitudinal clinical trajectories and immune remodeling for continuous risk assessment during PD-1 inhibitor therapy. Dynamic clinical and immune features provided complementary predictive information beyond baseline characteristics, supporting an adaptive approach for precision immunotherapy monitoring in gastric cancer.
- 27 March 2026
- Published by Elsevier in Life Sciences
- Vol. 394, 124358
Membrane protein-focused CRISPR screen identifies ATP2A2 as a druggable transcriptional co-regulator of CCND1 (cyclin D1) in lung adenocarcinoma
- 27 March 2026
- Published by Elsevier in Life Sciences
- Vol. 394, 124358
Membrane protein-focused CRISPR screen identifies ATP2A2 as a druggable transcriptional co-regulator of CCND1 (cyclin D1) in lung adenocarcinoma
- Open Access
- 2 October 2025
- Published by Springer Nature in Molecular Cancer
- Vol. 24 (1) , 1-20
BRD9-p53-E2F1 circuit orchestrates cell growth and DNA damage repair in gastric cancer
BRD9 is involved in multiple physiological and pathological pathways, yet its functional role and molecular mechanisms in gastric cancer (GC) remain largely unexplored. Addressing this knowledge gap is critical given the persistent global mortality burden of GC and the limited efficacy of current therapeutic strategies. BRD9 expression in GC patients was systematically analyzed using immunohistochemical (IHC) assays and transcriptomic datasets. Comprehensive functional validation, employing cellular and murine tumor models, elucidated BRD9’s role in GC progression. Molecular pathways underlying BRD9-mediated gastric carcinogenesis were delineated through integrated approaches, including RNA sequencing, co-immunoprecipitation (co-IP), subcellular fractionation, and luciferase reporter assays. BRD9 was significantly overexpressed in GC and associated with poor patient prognosis. Functionally, BRD9 promoted GC cell proliferation and enhanced DNA damage repair capacity. Mechanistically, elevated BRD9 expression inhibited p53 nuclear translocation via direct binding, subsequently activating the E2F transcription factor family. Notably, we identified that E2F1 directly bound to and transactivated the BRD9 promoter, establishing a positive feedback loop that sustains BRD9 expression. Additionally, BRD9 knockdown sensitized GC cells to cisplatin and oxaliplatin treatment. These findings highlight the critical role of BRD9 in GC progression and its therapeutic potential. The BRD9-p53-E2F1 axis acts as a crucial regulator of GC cell proliferation and DNA damage response. Targeting BRD9 pharmacologically could be a novel therapeutic approach to enhance chemotherapy efficacy and improve treatment outcomes in GC patients.
- 2 October 2025
- Published by Springer Nature in Molecular Cancer
- Vol. 24 (1) , 1-20
Open AccessBRD9-p53-E2F1 circuit orchestrates cell growth and DNA damage repair in gastric cancer
BRD9 is involved in multiple physiological and pathological pathways, yet its functional role and molecular mechanisms in gastric cancer (GC) remain largely unexplored. Addressing this knowledge gap is critical given the persistent global mortality burden of GC and the limited efficacy of current therapeutic strategies. BRD9 expression in GC patients was systematically analyzed using immunohistochemical (IHC) assays and transcriptomic datasets. Comprehensive functional validation, employing cellular and murine tumor models, elucidated BRD9’s role in GC progression. Molecular pathways underlying BRD9-mediated gastric carcinogenesis were delineated through integrated approaches, including RNA sequencing, co-immunoprecipitation (co-IP), subcellular fractionation, and luciferase reporter assays. BRD9 was significantly overexpressed in GC and associated with poor patient prognosis. Functionally, BRD9 promoted GC cell proliferation and enhanced DNA damage repair capacity. Mechanistically, elevated BRD9 expression inhibited p53 nuclear translocation via direct binding, subsequently activating the E2F transcription factor family. Notably, we identified that E2F1 directly bound to and transactivated the BRD9 promoter, establishing a positive feedback loop that sustains BRD9 expression. Additionally, BRD9 knockdown sensitized GC cells to cisplatin and oxaliplatin treatment. These findings highlight the critical role of BRD9 in GC progression and its therapeutic potential. The BRD9-p53-E2F1 axis acts as a crucial regulator of GC cell proliferation and DNA damage response. Targeting BRD9 pharmacologically could be a novel therapeutic approach to enhance chemotherapy efficacy and improve treatment outcomes in GC patients.
- Open Access
- 30 April 2025
- Published by MDPI AG in Current Oncology
- Vol. 32 (5) , 262
The Spatial Proximity of CD8+ FoxP3+PD-1+ Cells to Tumor Cells: A More Accurate Predictor of Immunotherapy Outcomes in Advanced Non-Small-Cell Lung Cancer
Background: To optimize precision immunotherapy for advanced NSCLC, comprehensive tumor immune microenvironment (TIME) characterization is crucial for efficacy prediction. Methods: Pretreatment tumor samples from 46 advanced NSCLC patients treated with PD-1/PD-L1 inhibitors were analyzed. The subregional abundance and spatial proximity scores of TIME cell subpopulations in 27 samples were assessed via multiplex immunohistochemistry (mIHC) targeting pan-CK, CD163, CD8, FoxP3, PD-1, and PD-L1. Correlations between the TIME features, clinicopathologic factors, treatment response, and prognosis were evaluated. Results: CD8+FoxP3+ cells were identified in NSCLC tissues, predominantly expressing PD-1/PD-L1. The PD-L1 TPS subgroups showed significant immune cell density/proximity differences, but CD8+FoxP3+PD-1+ infiltration was PD-L1 TPS-independent. Responders had higher CD8+FoxP3+PD-1high density (p = 0.0497) and proximity scores (p = 0.0099) than non-responders. The CD8+FoxP3+PD-1+ presence and tumor proximity were essential for favorable outcomes. In low-PD-L1 TPS patients, the CD8+FoxP3+PD-1+ abundance and proximity scores strongly predicted the response (AUC: 0.79 and 0.75 vs. PD-L1 TPS AUC = 0.58). A survival analysis linked the presence and proximity score of CD8+FoxP3+PD-1+ cells to prolonged overall survival (OS) and progression-free survival (PFS). Notably, a low proximity score of CD8+FoxP3+PD-1+ cells emerged as an independent risk factor for a shorter PFS (HR = 6.16, 95% CI: 2.12–17.93, p = 0.001). Conclusion: The CD8+FoxP3+PD-1+ spatial proximity to tumor cells robustly predicts improved immunotherapy outcomes in advanced NSCLC.
- 30 April 2025
- Published by MDPI AG in Current Oncology
- Vol. 32 (5) , 262
Open AccessThe Spatial Proximity of CD8+ FoxP3+PD-1+ Cells to Tumor Cells: A More Accurate Predictor of Immunotherapy Outcomes in Advanced Non-Small-Cell Lung Cancer
Background: To optimize precision immunotherapy for advanced NSCLC, comprehensive tumor immune microenvironment (TIME) characterization is crucial for efficacy prediction. Methods: Pretreatment tumor samples from 46 advanced NSCLC patients treated with PD-1/PD-L1 inhibitors were analyzed. The subregional abundance and spatial proximity scores of TIME cell subpopulations in 27 samples were assessed via multiplex immunohistochemistry (mIHC) targeting pan-CK, CD163, CD8, FoxP3, PD-1, and PD-L1. Correlations between the TIME features, clinicopathologic factors, treatment response, and prognosis were evaluated. Results: CD8+FoxP3+ cells were identified in NSCLC tissues, predominantly expressing PD-1/PD-L1. The PD-L1 TPS subgroups showed significant immune cell density/proximity differences, but CD8+FoxP3+PD-1+ infiltration was PD-L1 TPS-independent. Responders had higher CD8+FoxP3+PD-1high density (p = 0.0497) and proximity scores (p = 0.0099) than non-responders. The CD8+FoxP3+PD-1+ presence and tumor proximity were essential for favorable outcomes. In low-PD-L1 TPS patients, the CD8+FoxP3+PD-1+ abundance and proximity scores strongly predicted the response (AUC: 0.79 and 0.75 vs. PD-L1 TPS AUC = 0.58). A survival analysis linked the presence and proximity score of CD8+FoxP3+PD-1+ cells to prolonged overall survival (OS) and progression-free survival (PFS). Notably, a low proximity score of CD8+FoxP3+PD-1+ cells emerged as an independent risk factor for a shorter PFS (HR = 6.16, 95% CI: 2.12–17.93, p = 0.001). Conclusion: The CD8+FoxP3+PD-1+ spatial proximity to tumor cells robustly predicts improved immunotherapy outcomes in advanced NSCLC.
- Open Access
- 5 August 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1421604
Plasma extracellular vesicle long RNA profiling identifies a predictive signature for immunochemotherapy efficacy in lung squamous cell carcinoma
Introduction: The introduction of Immune Checkpoint Inhibitors (ICIs) has marked a paradigm shift in treating Lung Squamous Cell Carcinoma (LUSC), emphasizing the urgent need for precise molecular biomarkers to reliably forecast therapeutic efficacy. This study aims to identify potential biomarkers for immunochemotherapy efficacy by focusing on plasma extracellular vesicle (EV)-derived long RNAs (exLRs).Methods: We enrolled 78 advanced LUSC patients undergoing first-line immunochemotherapy. Plasma samples were collected, and exLR sequencing was conducted to establish baseline profiles. A retrospective analysis was performed on 42 patients to identify differentially expressed exLRs. Further validation of the top differentially expressed exLRs was conducted using quantitative reverse transcription PCR (qRT-PCR). Univariate Cox analysis was applied to determine the prognostic significance of these exLRs. Based on these findings, we developed a predictive signature (p-Signature).Results: In the retrospective analysis of 42 patients, we identified 460 differentially expressed exLRs, with pathways related to leukocyte migration notably enriched among non-responders. Univariate Cox analysis revealed 45 exLRs with prognostic significance. The top 6 protein-coding exLRs were validated using qRT-PCR, identifying CXCL8, SSH3, and SDHAF1 as differentially expressed between responders and non-responders. The p-Signature, comprising these three exLRs, demonstrated high accuracy in distinguishing responders from non-responders, with an Area Under the Curve (AUC) of 0.904 in the retrospective cohort and 0.812 in the prospective cohort.Discussion: This study highlighted the potential of plasma exLR profiles in predicting LUSC treatment efficacy. Intriguingly, lower p-Signature scores were associated with increased abundance of activated CD4+ and CD8+ T cells, indicating a more robust immune environment. These findings suggest that the p-Signature could serve as a valuable tool in guiding personalized and effective therapeutic strategies for LUSC.
- 5 August 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1421604
Open AccessPlasma extracellular vesicle long RNA profiling identifies a predictive signature for immunochemotherapy efficacy in lung squamous cell carcinoma
Introduction: The introduction of Immune Checkpoint Inhibitors (ICIs) has marked a paradigm shift in treating Lung Squamous Cell Carcinoma (LUSC), emphasizing the urgent need for precise molecular biomarkers to reliably forecast therapeutic efficacy. This study aims to identify potential biomarkers for immunochemotherapy efficacy by focusing on plasma extracellular vesicle (EV)-derived long RNAs (exLRs).Methods: We enrolled 78 advanced LUSC patients undergoing first-line immunochemotherapy. Plasma samples were collected, and exLR sequencing was conducted to establish baseline profiles. A retrospective analysis was performed on 42 patients to identify differentially expressed exLRs. Further validation of the top differentially expressed exLRs was conducted using quantitative reverse transcription PCR (qRT-PCR). Univariate Cox analysis was applied to determine the prognostic significance of these exLRs. Based on these findings, we developed a predictive signature (p-Signature).Results: In the retrospective analysis of 42 patients, we identified 460 differentially expressed exLRs, with pathways related to leukocyte migration notably enriched among non-responders. Univariate Cox analysis revealed 45 exLRs with prognostic significance. The top 6 protein-coding exLRs were validated using qRT-PCR, identifying CXCL8, SSH3, and SDHAF1 as differentially expressed between responders and non-responders. The p-Signature, comprising these three exLRs, demonstrated high accuracy in distinguishing responders from non-responders, with an Area Under the Curve (AUC) of 0.904 in the retrospective cohort and 0.812 in the prospective cohort.Discussion: This study highlighted the potential of plasma exLR profiles in predicting LUSC treatment efficacy. Intriguingly, lower p-Signature scores were associated with increased abundance of activated CD4+ and CD8+ T cells, indicating a more robust immune environment. These findings suggest that the p-Signature could serve as a valuable tool in guiding personalized and effective therapeutic strategies for LUSC.
- Open Access
- 1 July 2024
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 16 (7) , 4567-4583
Identification of a prognostic gene signature in patients with cisplatin resistant squamous cell lung cancer
Background: In the absence of targeted mutations and immune checkpoints, platinum-based chemotherapy remains a gold standard agent in the treatment of patients with lung squamous cell carcinoma (LUSC). However, cisplatin resistance greatly limits its therapeutic efficacy and presents challenges in the treatment of lung cancer patients. Therefore, the potential clinical needs for this research focus on identifying novel molecular signatures to further elucidate the underlying mechanisms of cisplatin resistance in LUSC. A growing body of evidence indicates that alternative splicing (AS) events significantly influence the tumor progression and survival of patients with LUSC. However, there are few systematic analyses of AS reported in LUSC. This study aims to explore the role of messenger RNA (mRNA), microRNA (miRNA), and AS in predicting prognosis in patients with cisplatin-resistant LUSC and provide potential therapeutic targets and drugs. Methods: Gene expression and miRNA expression, using RNA sequencing (RNA-seq), and SpliceSeq data were downloaded from The Cancer Genome Atlas (TCGA) database. The least absolute shrinkage and selection operator (LASSO) Cox regression analysis were used to construct predictive models. Kaplan-Meier survival analyses were used to evaluate patients’ prognosis. Single-sample gene set enrichment analysis (ssGSEA) conducted via the R package “GSEAbase” was used to evaluate the immune-related characteristics. Immunohistochemistry was used to examine protein expression. The Connectivity Map (CMap) database was used to screen for potential drugs. The 3-(4,5)-dimethylthiahiazo (-z-y1)-3,5-di-phenytetrazoliumromide (MTT) assay was used to determine and calculate the half-maximal inhibitory concentration (IC50) of the drugs, sulforaphane and parthenolide. Results: In this study, bioinformatics were used to identify mRNAs, miRNAs, and AS events related to response to cisplatin and to establish an integrated prognostic signature for 70 patients with LUSC and cisplatin resistance. The prognostic signature served as an independent prognostic factor with high accuracy [hazard ratio (HR) =2.346, 95% confidence interval (CI): 1.568–3.510; PConclusions: This study provides a framework for the mRNA-, miRNA-, and AS-based evaluation of cisplatin response and several potential therapeutic drugs for targeting cisplatin resistance in LUSC. These findings may serve as a theoretical basis for the clinical alleviation of cisplatin resistance and thus help to improve treatment responses to chemotherapy in patients with LUSC.
- 1 July 2024
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 16 (7) , 4567-4583
Open AccessIdentification of a prognostic gene signature in patients with cisplatin resistant squamous cell lung cancer
Background: In the absence of targeted mutations and immune checkpoints, platinum-based chemotherapy remains a gold standard agent in the treatment of patients with lung squamous cell carcinoma (LUSC). However, cisplatin resistance greatly limits its therapeutic efficacy and presents challenges in the treatment of lung cancer patients. Therefore, the potential clinical needs for this research focus on identifying novel molecular signatures to further elucidate the underlying mechanisms of cisplatin resistance in LUSC. A growing body of evidence indicates that alternative splicing (AS) events significantly influence the tumor progression and survival of patients with LUSC. However, there are few systematic analyses of AS reported in LUSC. This study aims to explore the role of messenger RNA (mRNA), microRNA (miRNA), and AS in predicting prognosis in patients with cisplatin-resistant LUSC and provide potential therapeutic targets and drugs. Methods: Gene expression and miRNA expression, using RNA sequencing (RNA-seq), and SpliceSeq data were downloaded from The Cancer Genome Atlas (TCGA) database. The least absolute shrinkage and selection operator (LASSO) Cox regression analysis were used to construct predictive models. Kaplan-Meier survival analyses were used to evaluate patients’ prognosis. Single-sample gene set enrichment analysis (ssGSEA) conducted via the R package “GSEAbase” was used to evaluate the immune-related characteristics. Immunohistochemistry was used to examine protein expression. The Connectivity Map (CMap) database was used to screen for potential drugs. The 3-(4,5)-dimethylthiahiazo (-z-y1)-3,5-di-phenytetrazoliumromide (MTT) assay was used to determine and calculate the half-maximal inhibitory concentration (IC50) of the drugs, sulforaphane and parthenolide. Results: In this study, bioinformatics were used to identify mRNAs, miRNAs, and AS events related to response to cisplatin and to establish an integrated prognostic signature for 70 patients with LUSC and cisplatin resistance. The prognostic signature served as an independent prognostic factor with high accuracy [hazard ratio (HR) =2.346, 95% confidence interval (CI): 1.568–3.510; PConclusions: This study provides a framework for the mRNA-, miRNA-, and AS-based evaluation of cisplatin response and several potential therapeutic drugs for targeting cisplatin resistance in LUSC. These findings may serve as a theoretical basis for the clinical alleviation of cisplatin resistance and thus help to improve treatment responses to chemotherapy in patients with LUSC.